Lianyungang, China

Chao Jin

This inventor holds 1 USPTO granted patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chao Jin. Retrieved from https://idiyas.com/inventor/chao-jin-xeu00ekw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Chao Jin

Introduction

Chao Jin is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical applications. His work focuses on creating effective treatments for diseases related to Bruton’s tyrosine kinase (BTK).

Latest Patents

Chao Jin holds a patent for a furo[3,4-b]pyrrole-containing BTK inhibitor. This patent pertains to a compound that is designed to treat BTK-related diseases. The invention includes a preparation method for the compound, as well as a pharmaceutical composition that incorporates it. The compound can exist in various forms, including stereoisomers and pharmacologically acceptable salts.

Career Highlights

Chao Jin is affiliated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he applies his expertise in pharmaceutical chemistry. His work has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Chao Jin collaborates with esteemed colleagues such as Yinsheng Zhang and Hongjiang Xu. Their combined efforts enhance the research and development capabilities within their organization.

Conclusion

Chao Jin's innovative work in pharmaceutical chemistry exemplifies the impact of dedicated inventors in the medical field. His contributions, particularly in developing BTK inhibitors, are paving the way for new treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…